109 related articles for article (PubMed ID: 9873412)
1. N3-methyl-mafosfamide as a chemically stable, alternative prodrug of mafosfamide.
Moon KY; Kwon CH
Bioorg Med Chem Lett; 1998 Jul; 8(13):1673-8. PubMed ID: 9873412
[TBL] [Abstract][Full Text] [Related]
2. Chemically stable N-methyl-4-(alkylthio)cyclophosphamide derivatives as prodrugs of 4-hydroxycyclophosphamide.
Moon KY; Shirota FN; Baturay N; Kwon CH
J Med Chem; 1995 Mar; 38(5):848-51. PubMed ID: 7877150
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine.
Maki PA; Sladek NE
Cancer Res; 1991 Aug; 51(16):4170-5. PubMed ID: 1868438
[TBL] [Abstract][Full Text] [Related]
4. Chemically stable, lipophilic prodrugs of phosphoramide mustard as potential anticancer agents.
Kwon CH; Moon KY; Baturay N; Shirota FN
J Med Chem; 1991 Feb; 34(2):588-92. PubMed ID: 1995881
[TBL] [Abstract][Full Text] [Related]
5. New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug.
Skórski T; Kawalec M
Invest New Drugs; 1987; 5(2):167-9. PubMed ID: 3654151
[TBL] [Abstract][Full Text] [Related]
6. Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.
Kawalec M; Skórski T; Kawiak J
Invest New Drugs; 1988 Sep; 6(3):169-72. PubMed ID: 3192382
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic and nondividing mafosfamide-treated L 1210 cells--comparison of lines resistant and nonresistant to cyclophosphamide.
Kawalec M; Hoser G; Skórski T; Kawiak J
Folia Histochem Cytobiol; 1993; 31(2):63-6. PubMed ID: 8405569
[TBL] [Abstract][Full Text] [Related]
8. Induction of immune resistance against L1210 lymphatic leukemia in mice after chemoradiotherapy of the leukemia and reconstitution with bone marrow purged from the leukemia with mafosfamide.
Skórski T; Kawalec M
Exp Hematol; 1988 Oct; 16(9):782-4. PubMed ID: 3049130
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of aldehyde dehydrogenases in murine tumor and hematopoietic progenitor cells to inhibition by chloral hydrate as determined by the ability of chloral hydrate to potentiate the cytotoxic action of mafosfamide.
Maki PA; Sladek NE
Biochem Pharmacol; 1993 Jan; 45(1):231-9. PubMed ID: 8424816
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide.
Uckun FM; Chandan-Langlie M; Dockham PA; Aeppli D; Sladek NE
Leuk Lymphoma; 1994 May; 13(5-6):417-28. PubMed ID: 8069187
[TBL] [Abstract][Full Text] [Related]
11. Recovery of the ability to induce immune resistance against L1210 lymphatic leukemia in semisyngeneic CD2F1 mice after lethal irradiation and reconstitution with bone marrow purged of leukemia with mafosfamide (ASTA Z 7654).
Skórski T; Kawalec M
Bone Marrow Transplant; 1987 Dec; 2(4):435-40. PubMed ID: 3332191
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the effects of ifosfamide vs. mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets.
Botzler C; Kis K; Issels R; Multhoff G
Exp Hematol; 1997 Apr; 25(4):338-44. PubMed ID: 9131009
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.
Reissmann T; Voegeli R; Pohl J; Hilgard P
Cancer Immunol Immunother; 1989; 28(3):179-84. PubMed ID: 2924329
[TBL] [Abstract][Full Text] [Related]
14. Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness.
Greenwald RB; Gilbert CW; Pendri A; Conover CD; Xia J; Martinez A
J Med Chem; 1996 Jan; 39(2):424-31. PubMed ID: 8558510
[TBL] [Abstract][Full Text] [Related]
15. Oxazaphosphorine effects in L 5222 rat leukemia.
Pohl J; Reissmann T; Voegeli R
Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):589-94. PubMed ID: 3437788
[TBL] [Abstract][Full Text] [Related]
16. Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557).
Kohn FR; Sladek NE
Biochem Pharmacol; 1987 Sep; 36(17):2805-11. PubMed ID: 2820422
[TBL] [Abstract][Full Text] [Related]
17. Effects of N-substitution on the activation mechanisms of 4-hydroxycyclophosphamide analogues.
Kwon CH; Borch RF
J Med Chem; 1989 Jul; 32(7):1491-6. PubMed ID: 2738883
[TBL] [Abstract][Full Text] [Related]
18. C-myc expression is down-regulated in mafosfamide-treated HL-60 cells undergoing apoptosis.
Davidoff AN; Mendelow BV
Anticancer Res; 1993; 13(4):1167-70. PubMed ID: 8352540
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antitumor properties of activated cyclophosphamide analogues.
Borch RF; Canute GW
J Med Chem; 1991 Oct; 34(10):3044-52. PubMed ID: 1920355
[TBL] [Abstract][Full Text] [Related]
20. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
